Skip to main content
    R

    Rocket Pharmaceuticals Inc (RCKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.16
    -0.14 (-6.09%)

    Market Cap: $256.82M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rocket Pharmaceuticals Inc (RCKT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Rocket Pharmaceuticals (RCKT) to earn -$0.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.11M. Of 14 analysts, 7 rate the stock Buy or Strong Buy, 6 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.57, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.

    RatingAnalystsShare
    Strong Buy17.1%
    Buy642.9%
    Hold642.9%
    Sell00.0%
    Strong Sell17.1%
    Consensus
    Hold
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 913.5%.

    Fiscal year ending Dec 31, 2026
    -$0.11
    EPS consensus, revenue $1.11M
    Fiscal year ending Dec 31, 2027
    -$1.60
    EPS consensus, revenue $11.25M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.11-$0.20 to $0.084$1.11MN/A12
    Dec 31, 2027-$1.60-$1.84 to -$1.314$11.25MN/A12

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.42-$0.45 to -$0.2515$612000N/A13

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.90.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.11-$0.11-$0.11-$0.11-$0.90N/A
    Fiscal year ending Dec 31, 2027-$1.60-$1.30-$1.30-$1.30-$1.22N/A

    Frequently Asked Questions About RCKT

    What is the RCKT stock forecast?

    Consensus analyst estimates put Rocket Pharmaceuticals's EPS at -$0.11 for the fiscal year ending Dec 31, 2026, on revenue of $1.11M. The consensus rating from 14 analysts is Hold.

    How do analysts rate RCKT stock?

    Of 14 analysts covering Rocket Pharmaceuticals, 1 rates it Strong Buy, 6 Buy, 6 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from RCKT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.11, with estimates from -$0.20 to $0.08 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.60, with estimates from -$1.84 to -$1.31 from 4 analysts.

    What revenue do analysts expect from Rocket Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.11M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.25M.

    How many analysts cover RCKT?

    14 analysts rate Rocket Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.